Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
Tevogen (NASDAQ:TVGN) has expressed support for the White House's "Winning the Race: America's AI Action Plan" released on July 23, 2025. The company has developed PredicTcell™, an alpha version machine learning model, in partnership with Microsoft and Databricks.
The proprietary AI model is designed to significantly reduce target analysis time in immunotherapy research, potentially resulting in billions in cost savings for drug development. This aligns with the government's initiative to accelerate AI innovation and adoption in healthcare through domain-specific standards, regulatory sandboxes, and stakeholder convenings led by The National Institute of Standards and Technology.
The company, under CEO Ryan Saadi's leadership, emphasizes its commitment to developing scalable, ethical AI solutions to improve access to affordable advanced therapeutics.Tevogen (NASDAQ:TVGN) ha espresso il proprio sostegno al piano "Winning the Race: America's AI Action Plan" presentato dalla Casa Bianca il 23 luglio 2025. L'azienda ha sviluppato PredicTcell™, una versione alpha di un modello di machine learning, in collaborazione con Microsoft e Databricks.
Questo modello AI proprietario è progettato per ridurre significativamente i tempi di analisi dei target nella ricerca sull'immunoterapia, con un potenziale risparmio di miliardi nei costi di sviluppo farmaceutico. Ciò si allinea con l'iniziativa governativa volta ad accelerare l'innovazione e l'adozione dell'IA nel settore sanitario attraverso standard specifici per il dominio, sandbox regolatori e incontri tra stakeholder guidati dal National Institute of Standards and Technology.
Sotto la guida del CEO Ryan Saadi, la società sottolinea il proprio impegno a sviluppare soluzioni AI scalabili ed etiche per migliorare l'accesso a terapie avanzate e accessibili.
Tevogen (NASDAQ:TVGN) ha expresado su apoyo al plan "Winning the Race: America's AI Action Plan" presentado por la Casa Blanca el 23 de julio de 2025. La empresa ha desarrollado PredicTcell™, una versión alfa de un modelo de aprendizaje automático, en colaboración con Microsoft y Databricks.
Este modelo de IA propietario está diseñado para reducir significativamente el tiempo de análisis de objetivos en la investigación de inmunoterapia, con un potencial ahorro de miles de millones en costos para el desarrollo de medicamentos. Esto se alinea con la iniciativa gubernamental para acelerar la innovación y adopción de IA en la salud mediante estándares específicos del dominio, entornos regulatorios de prueba y reuniones de partes interesadas lideradas por el National Institute of Standards and Technology.
Bajo el liderazgo del CEO Ryan Saadi, la compañía enfatiza su compromiso con el desarrollo de soluciones de IA escalables y éticas para mejorar el acceso a terapias avanzadas y asequibles.
Tevogen (NASDAQ:TVGN)은 2025년 7월 23일 백악관에서 발표한 "Winning the Race: America's AI Action Plan"을 지지한다고 밝혔습니다. 회사는 Microsoft와 Databricks와 협력하여 알파 버전의 머신러닝 모델인 PredicTcell™을 개발했습니다.
이 독자적인 AI 모델은 면역 치료 연구에서 타겟 분석 시간을 크게 단축하도록 설계되어, 신약 개발 비용에서 수십억 달러의 절감 효과를 가져올 수 있습니다. 이는 국가표준기술연구소(NIST)가 주도하는 도메인별 표준, 규제 샌드박스, 이해관계자 회의를 통해 의료 분야 AI 혁신과 도입을 가속화하려는 정부의 계획과 부합합니다.
CEO 라이언 사아디(Ryan Saadi)의 리더십 아래, 회사는 확장 가능하고 윤리적인 AI 솔루션 개발에 전념하여 저렴한 첨단 치료제 접근성을 향상시키겠다는 의지를 강조하고 있습니다.
Tevogen (NASDAQ:TVGN) a exprimé son soutien au plan « Winning the Race: America's AI Action Plan » publié par la Maison Blanche le 23 juillet 2025. L'entreprise a développé PredicTcell™, une version alpha d'un modèle d'apprentissage automatique, en partenariat avec Microsoft et Databricks.
Ce modèle d'IA propriétaire est conçu pour réduire considérablement le temps d'analyse des cibles dans la recherche en immunothérapie, ce qui pourrait entraîner des économies de plusieurs milliards dans le développement de médicaments. Cela s'inscrit dans l'initiative gouvernementale visant à accélérer l'innovation et l'adoption de l'IA dans le domaine de la santé grâce à des normes spécifiques au domaine, des bacs à sable réglementaires et des réunions des parties prenantes dirigées par le National Institute of Standards and Technology.
Sous la direction du PDG Ryan Saadi, l'entreprise souligne son engagement à développer des solutions d'IA évolutives et éthiques pour améliorer l'accès à des thérapies avancées abordables.
Tevogen (NASDAQ:TVGN) hat seine Unterstützung für den am 23. Juli 2025 von der US-Regierung veröffentlichten Plan „Winning the Race: America's AI Action Plan“ bekundet. Das Unternehmen hat in Zusammenarbeit mit Microsoft und Databricks das Alpha-Modell PredicTcell™ entwickelt.
Dieses proprietäre KI-Modell ist darauf ausgelegt, die Analysezeiten von Zielstrukturen in der Immuntherapieforschung erheblich zu verkürzen, was potenziell Milliarden an Kosteneinsparungen bei der Arzneimittelentwicklung ermöglichen kann. Dies steht im Einklang mit der Regierungsinitiative, die Innovation und Einführung von KI im Gesundheitswesen durch domänenspezifische Standards, regulatorische Sandboxes und Stakeholder-Treffen unter Leitung des National Institute of Standards and Technology zu beschleunigen.
Unter der Führung von CEO Ryan Saadi betont das Unternehmen sein Engagement für die Entwicklung skalierbarer, ethischer KI-Lösungen, um den Zugang zu erschwinglichen, fortschrittlichen Therapien zu verbessern.
- Development of PredicTcell™ AI model that reduces immunotherapy research time
- Strategic partnerships with major tech companies Microsoft and Databricks
- Potential for significant cost reduction in drug development process
- Alignment with government AI initiatives in healthcare
- PredicTcell™ is still in alpha version, indicating early development stage
- Need for additional capital to execute business plan
- Limited operating history as mentioned in risk factors
Insights
Tevogen's new AI model developed with Microsoft could significantly reduce immunotherapy R&D costs while aligning with new government AI priorities.
Tevogen's announcement reveals a strategic positioning at the intersection of two high-growth sectors: healthcare and artificial intelligence. The company has developed an alpha version of PredicTcell™, a machine learning model created in partnership with tech giants Microsoft and Databricks. This collaboration with established technology leaders adds significant credibility to Tevogen's AI capabilities.
The technical achievement is noteworthy: PredicTcell™ reportedly accelerates target analysis in immunotherapy research by weeks, potentially translating to billions in cost savings during drug development. This addresses one of the pharmaceutical industry's most pressing challenges - the astronomical costs and lengthy timelines of bringing new therapies to market.
What makes this announcement particularly timely is its alignment with the White House's newly released "Winning the Race: America's AI Action Plan." By positioning themselves as supporting government initiatives focused on healthcare AI innovation, Tevogen could potentially benefit from regulatory sandboxes, collaborative frameworks, and possibly federal funding opportunities outlined in the plan.
While the press release emphasizes potential, it's important to note that PredicTcell™ remains in alpha version, indicating early-stage development with commercial applications likely still on the horizon. Investors should recognize that real-world validation of cost-saving claims and widespread adoption would be critical milestones to monitor as this technology matures.
WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House’s release of “Winning the Race: America’s AI Action Plan”, issued July 23, 2025. The Company applauds the federal government’s emphasis on establishing domain-specific standards, regulatory sandboxes (aka AI Centers of Excellence), and stakeholder convenings led by The National Institute of Standards and Technology to build trust, governance, and productivity in healthcare AI.
Aligned with AI Action Plan healthcare priorities, Tevogen.AI has recently developed the alpha version of PredicTcell™, a proprietary machine learning model built in collaboration with Microsoft (Nasdaq: MSFT) and Databricks. This model cuts weeks off target analysis in immunotherapy research, potentially saving billions in drug development costs. The approach reflects the Action Plan’s call for rapid scientific AI innovation and improved adoption of AI technology in the healthcare sector.
“As a mission-driven innovator, Tevogen.AI believes that AI has the potential to significantly reduce the cost and time required to bring life-saving treatments to patients in need,” said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen. “We commend the U.S. government for recognizing this potential and setting a national strategy. With a focus on both innovation and equity, our work at Tevogen.AI seeks scalable, ethical solutions that expand access to affordable, advanced therapeutics for all Americans.”
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is Tevogen's new AI technology PredicTcell™ and what does it do?
How does Tevogen's AI initiative align with the U.S. government's AI Action Plan?
Who are Tevogen's key partners in AI development?
What are the main challenges facing Tevogen's AI development plans?
Who is leading Tevogen's AI initiatives?
